Propanc Biopharma plans Phase 1b study of PRP proenzyme therapy in advanced solid tumors
PPCB•Phase 1b study plan for PRP proenzyme therapy
Propanc Biopharma plans a Phase 1b study of PRP, a once-weekly IV combination of trypsinogen and chymotrypsinogen, in advanced solid tumors.
The company outlined PRP as a differentiation-based approach for RAS-driven cancers.
Clinical development plan and regulatory status
The development plan targets a Phase 1b first-in-human study in up to 40-45 advanced solid-tumor patients, with a clinical trial filing planned for Q4.
Propanc also cited FDA Orphan Drug Designation for pancreatic cancer and prior compassionate-use experience that it said showed prolonged survival signals without severe treatment-related adverse events.
Preclinical data cited for pancreatic cancer models
Propanc said preclinical PDAC studies showed:
- More than 90% mean tumor growth inhibition in orthotopic and PDX models
- Marked reduction in metastasis
- Median survival more than 2.5 times longer (p < 0.001)
The program is positioned as non-cytotoxic and aimed at reversing EMT and reducing cancer stem-cell traits linked to recurrence and treatment resistance.
